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The Relationship Between Serum Adiponectin,Tumor
Necrosis Factor-Alpha, Leptin Levels and Insulin
Sensitivity in Childhood and Adolescent Obesity:




Obesity and insulin resistance are on their way to become
commonly encountered conditions both in childhood and 
adolescence. This is accompanied by an increase in the 
number of young obese populations with the metabolic
syndrome (MS). The features of MS include insulin resistance,
glucose intolerance, hypertension, dyslipidemia and central
obesity. All these parameters are risk factors for coronary 
heart disease and type 2 diabetes mellitus (T2DM). Several
new features, such as the decrease of adiponectin and the 
increase of plasminogen activator inhibitor-1 (PAI-1) and 
C-reactive protein (CRP) have been recently added to the 
definition of MS, which is considered as a low-grade 
inflammatory state. 
Adipose tissue is currently considered to be hormonally 
active and to take part in the control of metabolism. Adipose
tissue secretes a large number of physiologically active 
peptides that have common properties with cytokines, and
therefore referred to as adipocytokines. Leptin, tumor necrosis
factor-alpha (TNF-α), PAI-1, interleukin-6 (IL-6) and adiponectin
are some of these adipocytokines. Adiponectin is specifically
expressed in human adipocytes. Plasma adiponectin 
concentration is decreased in individuals with obesity, and
body-weight reduction increases its concentration (1-4). 
Several studies have suggested that adiponectin may have a
role in the modulation of glucose metabolism and insulin 
sensitivity  (5-10). Recent studies have demonstrated that 
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O Ob bj je ec ct ti iv ve e: :   This study aimed (a) to investigate the relationship between the
degree of obesity and serum adiponectin, tumor necrosis factor (TNF)-α, leptin,
insulin levels and the lipid profile; (b) to clarify the relationship between insulin
resistance/glucose tolerance and adipocytokine levels; and (c) to investigate the
value of adipocytokine levels as a marker of metabolic syndrome (MS).
M Me et th ho od ds s: :   We studied 151 obese children and adolescents (86 boys and 65
girls; mean age was 12.3±2.4 years). We defined obesity as a body-mass index
(BMI) z-score more than 2 SD above the mean for age and sex. The control
group consisted of 100 children (48 boys, 52 girls, mean age 12.4±2.5 years).
Fasting glucose, insulin levels and lipid profiles were measured in all cases
and controls after a 12-hour fast. Adiponectin, TNF-α, and leptin levels were
measured in the subjects who participated in the adipocytokine branch of the
study. An oral glucose tolerance test (OGTT) was also performed in all obese
patients. Obese patients were grouped into three subgroups according to their
glucose tolerance and insulin sensitivity assessment, and also according to
whether they were grouped as MS or not.
R Re es su ul lt ts s: :   Serum levels of total cholesterol, LDL and VLDL cholesterol, log
triglyceride, insulin, leptin and TNF-α were higher, whereas HDL and square
root adiponectin levels were lower in the obese group when compared with
controls. Multiple regression analysis among BMI-z score, LDL, triglyceride,
HOMA-IR, leptin and TNF-α as determinants of adiponectin revealed that
BMI-z score was the only determinant for adiponectin (r:-0.45, p<0.0001).
Adiponectin levels in hyperinsulinemic and impaired glucose tolerance groups
(IGT) tended to be lower than in normoinsulinemic obese children, however,
the difference was not significant. There was a weak negative correlation
between adiponectin levels and increasing severity of insulin resistance 
(r=-0.23, p=0.005) in the groups of obese subjects. Mean serum adiponectin
level in subjects with MS was lower than in subjects without MS (p=0.008).
C Co on nc cl lu us si io on ns s: :   Evaluation of serum adiponectin levels might contribute to an
early intervention in obese children with MS.
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induced tyrosine phosphorylation of the insulin receptor in
skeletal muscle, resulting in improved glucose tolerance (11).
It is also suggested that adiponectin has an anti-inflammatory
effect on the vascular wall and also has an anti-atherosclerotic
effect by direct action on the endothelial cells (12-13). Clinical
studies have shown that adiponectin levels are lower in 
individuals with coronary artery disease (14-15). However,
the relationships between adiponectin levels and atheroscle-
rosis or metabolic abnormalities such as insulin resistance,
are still obscure. 
The aim of this study was to analyze (a) the relationship
between the degree of obesity and serum adiponectin, TNF-α,
leptin, insulin levels, lipid profile; (b) the relationship between
insulin resistance/glucose tolerance and adipocytokine levels;
and (c) the value of adipocytokine level as a marker of MS.
Methods
P Pa at ti ie en nt ts s   a an nd d   C Co on nt tr ro ol ls s
We studied 151 obese children and adolescents (86 boys
and 65 girls). The mean age of the patients was 12.3±2.4 
years (range 7-17 years). We defined obesity as a body-mass
index (BMI) z-score greater than 2 standard deviations above
the mean for age and sex. Due to the age range in the study
population z score was used for evaluation and a cutoff of 2
SD was taken instead of an absolute value of 30kg/m
2. The
control group consisted of 100 (48 boys, 52 girls) nonobese,
healthy children and adolescents who presented to the 
outpatient clinic for acute problems or routine check-up. The
mean age of the control group was 12.4±2.5 years (6-16.8 
years).
Height was measured to the nearest millimeter by a 
wall-mounted stadiometer, and weight was measured to the
nearest 100 g by SECA digital scale with light clothing. 
Fasting glucose, insulin levels and lipid profiles (total 
cholesterol, HDL, LDL, VLDL cholesterol, and triglycerides)
were assessed in all cases and controls after a 12-hour fast.
In obese subjects, thyroid function tests, diurnal cortisol 
levels, basal ACTH levels were also measured to exclude
hypothyroidism or hypercortisolism. An oral glucose tolerance
test (OGTT) was also performed in these subjects. 
Obese subjects and 29 controls (17 boys, 12 girls) agreed
to participate in the adipocytokine branch of the study. The
mean age of the 29 control cases was 12.7±2.6 years (range
7.6-18.2 years). This group was similar to the whole group
with respect to age, sex distribution, pubertal status and
BMI. Adiponectin, TNF-α, and leptin levels were measured in
the subjects who participated in the adipocytokine 
assessment. 
The patients were not receiving any antihypertensive 
medication or drugs that can interfere with glucose or lipid
metabolism at the time of the measurements.
C Ca al lc cu ul la at ti io on ns s   
The following calculations were made using respective
formulae: 
- Body-mass index (BMI) was calculated as: Weight
(kg)/height
2 (m). BMI z-score was calculated using the LMS
method  (16), according to the equation BMI z-score=
(BMI/M)L-1/LS, where L represents the Box-Cox power
transform required to remove the skewness from the 
distribution, M - the median of body mass index according to
age, and S - the coefficient of variation. 
- HOMA-IR was calculated as: Fasting insulin (μU/ml) x
fasting glucose (mmol/L) / 22.5. The cutoff point for insulin
sensitivity was determined as 4.17 using the 95th percentile
of HOMA-IR in 100 control cases. Since prepubertal 
subjects comprised less than 15% of both obese and 
control groups and the distribution of pubertal stages was
similar in both groups, this single cutoff level for HOMA-IR
was used. 
S St tu ud dy y   D De es si ig gn n
The following analyses were performed:
a) The clinical and biochemical characteristics of the 
obese population were compared with healthy controls. 
b) The effect of degree of obesity as determined by BMI-z
score on serum adipocytokine levels was analyzed by linear
correlation. BMI-z score and other parameters (LDL, 
triglyceride, HOMA-IR, leptin and TNF-α which may affect
adiponectin) were analyzed by multiple regression to find the
determinants of adiponectin.
c) The association between insulin resistance/glucose 
tolerance and adipocytokine levels was analyzed. For this
analysis obese patients were grouped into three subgroups
according to glucose tolerance and insulin sensitivity. WHO
criteria for glucose tolerance and our cutoff level for insulin
resistance as determined by HOMA-IR (4.17) were used to
group the patients as follows: 
Group 1 (n=90): Normal glucose tolerance and normoin-
sulinemia (NGT + NI)
Group 2 (n=44): Normal glucose tolerance and hyperinsu-
linemia (NGT + HI)
Group 3 (n=17): Impaired glucose tolerance or type 2 
diabetes mellitus (IGT or DM). Fifteen (9.9%) patients 
presented with impaired glucose tolerance (IGT) and two 
patients (1.3%) were diabetic. 
Leptin, TNF-α, and adiponectin levels of these groups
were compared.
d) We also analyzed the value of adipocytokine level as a
marker for MS. Obese patients were grouped according to
the presence or absence of MS. We used the modified 
criteria of Viner et al (17) for the diagnosis of MS (modified
from the National Cholesterol Education Program, Adult 
Treatment Panel). Dyslipidemia (triglyceride level >95th
percentile, HDL level <5th percentile), elevated blood 
pressure (systolic or diastolic blood pressure > 95th percentile),
IGT and insulin resistance were the four criteria of MS. The
patients were classified as having MS if they met 3 or more
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Adiponectin is a Marker of Metabolic Syndromeof these criteria for age and sex. Lipid Research Clinics Prog-
ram (LRCP) levels were used to define dyslipidemia (18). Blo-
od pressure nomograms for Turkish children and adolescents
were used to define hypertension (19). Seventy two obese
patients (47.6%) out of 151 were defined as having MS.
We compared adipocytokine levels of obese cases with
and without MS. 
The study was approved by the Ethics Committee of our
Institute, and informed consent was obtained from all 
subjects and their parents after a full explanation of the
study. 
A As ss sa ay ys s
Plasma glucose and lipid levels were measured by 
autoanalyzer (Roche Diagnostics). Plasma insulin levels were
measured using immunoradiometric assay (Biosource 
INS-IRMA kit). Plasma adiponectin levels were measured by
radioimmunoassay (Linco Laboratories). The intra- and 
inter-assay coefficients of variation were 4.5-7.6% and 
3.9-6.6%. TNF-α was measured using enzyme-linked 
immunosorbent assay (ELISA) (Biosource). The intra- and 
inter-assay coefficients of variation were 3.9-5.2% and 
5.9-8.5%. Leptin was measured using an immunoradiometric
assay (IRMA) (Diagnostic System Laboratories, Inc.). 
S St ta at ti is st ti ic ca al l   A An na al ly ys si is s
The comparisons of normally distributed parameters 
were carried out using the student’s t test. We used 
logarithmic (log) transformation for several variables (triglyceride,
HOMA-IR) since their distribution was skewed. Square root
transformation was used to convert adiponectin values to
normal distribution. We used Spearman’s correlation 
analysis, multiple regression, student’s t-test and ANOVA in
the analyses. Statistics Package for Social Sciences (SPSS)
version 13.0 was used for the statistical analyses. P values
<0.05 were considered significant.
Results
a a) )   C Co om mp pa ar ri is so on n   o of f   t th he e   c cl li in ni ic ca al l   a an nd d   b bi io oc ch he em mi ic ca al l   p pa ar ra am me et te er rs s
o of f   t th he e   s st tu ud dy y   p po op pu ul la at ti io on n   w wi it th h   c co on nt tr ro ol ls s
The clinical and biochemical characteristics of the study 
population are shown in Tables 1 and 2. Serum levels of total
cholesterol, LDL and VLDL cholesterol, log triglyceride, insulin,
leptin and TNF-α were higher (p<0.001; p<0.001; p<0.001;
p<0.0001; p=0.005; p<0.001; p<0.0001, respectively), whereas
HDL and square root adiponectin levels were lower (p<0.001)
in the obese group when compared to the controls.
b b) )   T Th he e   e ef ff fe ec ct t   o of f   d de eg gr re ee e   o of f   o ob be es si it ty y   o on n   s se er ru um m   a ad di ip po oc cy yt to ok ki in ne e
l le ev ve el ls s
BMI z-score was positively correlated to TNF-α, leptin, log
triglyceride, cholesterol, LDL, VLDL and log HOMA-IR 
(r=0.448, p<0.0001; r=0.682, p<0.0001; r=0.364, 
p<0.0001; r=0.243, p<0.001; r=0.267, p<0.0001, 
r=0.230, p=0.002; r=0.314, p<0.0001) and negatively 
correlated to the square root of adiponectin and HDL 
(r=-0.634, p <0.0001; r=- 0.281, p < 0.0001) (Figure 1).
Multiple regression analysis among BMI-z score, LDL,
triglyceride, HOMA-IR, leptin and TNF-α as determinants of
adiponectin revealed that BMI-z score was the only 
determinant for adiponectin (r=-0.45, p<0.0001).
c c) )    T Th he e    a as ss so oc ci ia at ti io on n    b be et tw we ee en n    i in ns su ul li in n    r re es si is st ta an nc ce e/ /g gl lu uc co os se e   
t to ol le er ra an nc ce e   a an nd d   a ad di ip po oc cy yt to ok ki in ne e   l le ev ve el ls s
Leptin, adiponectin and TNF-α levels of obese subjects
were significantly different than the controls. However, 
adipocytokine levels did not differ across groups of insulin
sensitivity among obese subjects. There was a weak negative
correlation between adiponectin levels against groups of
obese subjects with increasing severity of insulin resistance
(r=-0.23, p=0.005) (Table 3).
d d) )   T Th he e   v va al lu ue e   o of f   a ad di ip po oc cy yt to ok ki in ne e   l le ev ve el ls s   a as s   a a   m ma ar rk ke er r   o of f   M MS S
The baseline metabolic characteristics of obese patients
with MS are shown on Table 4. Mean serum adiponectin 
level in subjects with MS was 6.1±2.4 μg/ml, while this level
was 7.2±2.5 μg/ml in obese subjects without MS. The 
difference between the two groups was statistically 
significant (p=0.008).
The serum levels of leptin and TNF-α were comparable
between the two groups (p=0.547 and p=0.281). (Figure 2).
235
T Ta ab bl le e   2 2. .   Baseline metabolic characteristics of the study population
O Ob be es se e C Co on nt tr ro ol l
g gr ro ou up p g gr ro ou up p
( (n n= =1 15 51 1) ) ( (n n= =1 10 00 0) )
Fasting glucose (mg/dl) 84.6±7.1 87.9±8.1
Fasting insulin (μIU/ml) 20.6±18.6*** 10.3±4.5
HOMA-IR 4.3±3.9*** 2.3±1.2
Total cholesterol (mg/dl) 167.1±30.4** 154.6±29.6 
Triglyceride (mg/dl) 126.0±58.7* 69.1±25.0
HDL cholesterol (mg/dl) 47.6±10.3* 61.1±14.3
LDL cholesterol (mg/dl) 94.1±28.8** 77.5±26.4
VLDL cholesterol (mg/dl) 26.5±16.0** 14.2±6.5
Adiponectin (μg/ml)**** 6.7±2.5* 12.5±2.5
TNF-α (pg/ml)**** 17.3±5.9* 11.0±3.2
Leptin (ng/ml)**** 52.5±20.2* 7.2±4.9
Values are presented as the mean±SD
*   p<0.0001
**  p<0.001
*** p<0.005
**** Twenty nine control cases participated in the adipocytokine 
measurements
T Ta ab bl le e   1 1. .   Characteristics of the study population
O Ob be es se e C Co on nt tr ro ol l
g gr ro ou up p g gr ro ou up p
( (n n= =1 15 51 1) ) ( (n n= =1 10 00 0) )
Age,years(mean±SD)          12.3±2.4 12.4±2.5
Sex (n, M/F) 86/65 48/52
BMI, kg/m
2 (mean±SD) 28.8±4.0* 17.8±2.0
BMI Z-score (mean±SD) 2.7±0.4* 0.2±0.7
* p<0,0001
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Adiponectin is a Marker of Metabolic SyndromeDiscussion
The adipocytes are known to have an active endocrine
function; IL-6, TNF-α, PAI-1, leptin and adiponectin are 
produced in adipose tissue (20). Leptin and adiponectin are
the major adipocytokines secreted by fat cells. Leptin 
effects energy homeostasis by decreasing food intake and
by acting on lipogenesis and fatty acid oxidation. In contrast
to leptin, plasma adiponectin concentrations are inversely
related to adiposity. Evidence suggests that adiponectin 
inhibits the production and action of TNF-α (21). TNF-α
interferes with the insulin signaling cascade (21). Leptin and
adiponectin modify glucose and lipid metabolism, insulin
sensitivity, food intake, inflammatory processes and 
cardiovascular function. Although the physiological role of
adiponectin has not yet been fully elucidated, this protein
has been implicated in the pathophysiology of obesity-
related insulin resistance, glucose intolerance, insulin-
mediated lipoprotein metabolism, atherosclerosis, and co-
ronary heart disease (1,7,8,12,13,22).
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Figure 1. Relationship between adipocytokines and the degree of
obesity (BMI z-score)
Figure 2. Adipocytokine levels of obese patients with (MS) in compa-
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Adiponectin is a Marker of Metabolic SyndromeThe mechanisms responsible for the control of adiponectin
synthesis have not been determined so far. Insulin has been
the only hormone implicated in the regulation of adiponectin
expression. During a hyperinsulinemic-euglycemic glucose
clamp, adiponectin levels were suppressed below basal 
levels in both diabetic and non-diabetic patients (23). Weight
loss induces an increase in adiponectin levels in obese 
subjects. This state suggests the existence of a negative 
feedback mechanism between adipose mass and the 
production of adiponectin in humans (4). 
Studies in adults support the role of adiponectin in the 
pathogenesis of insulin resistance and T2DM (24-26). Several
studies demonstrated the association between adiponectin
and measures of insulin resistance also in the pediatric age
group (9, 27-30). Punthkee et al (31) showed that adiponectin
was not independently associated with markers of insulin 
resistance in youth. In our study, adipocytokine levels did not
differ within obese groups when they were grouped according
to insulin resistance and glucose tolerance. Adiponectin levels
in the groups with hyperinsulinemia and IGT tended to be 
lower than in normoinsulinemic obese children, however, the
difference was not significant. Lack of statistical significance
between adiponectin levels of obese children with different
degrees of glucose tolerance does not necessarily mean that
these two parameters are unrelated. The number of patients
in each group in the current study may be too small for such a
conclusion. Also, there are three isoforms of adiponectin in the
serum: low, middle and high molecular weight. Recent studies
showed that glucose tolerance is better correlated with the 
levels of high molecular weight (HMW) complexes in the 
serum rather than total adiponectin (32). HMW adiponectin
might be a better biomarker of insulin resistance than the 
commonly used measure of total adiponectin. The 
mechanisms implicated in lower adiponectin levels in subjects
with insulin resistance also remain obscure. TNF-α is one of
the candidate molecules responsible for causing insulin 
resistance. The expression and secretion of adiponectin from
adipocytes are significantly reduced by TNF-α. Therefore, 
increased TNF-α might be partially responsible for the 
decreased adiponectin production in obesity. 
In adults, epidemiological studies have shown that serum
adiponectin levels are negatively correlated with various 
indices of MS such as hypertension, insulin resistance, 
glucose intolerance and dyslipidemia. In 967 Japanese adult
subjects with normal weight, Yamamoto et al (26) have
shown that plasma adiponectin is negatively correlated with
BMI, systolic and diastolic blood pressure, fasting plasma 
glucose, insulin, insulin resistance, total and low-density 
lipoprotein-cholesterol, triglycerides and uric acid and 
positively correlated with high-density-lipoprotein cholesterol.
Lower plasma adiponectin levels are observed not only
among obese patients, but patients with T2DM and coronary
artery disease also have reduced adiponectin levels. Hotta et
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Table 3. Metabolic profile based on level of insulin sensitivity
C Co on nt tr ro ol ls s O Ob be es se e   g gr ro ou up p
N NG GT T+ +H HI I N NG GT T+ +N NI I I IG GT T+ +T Ty yp pe e   2 2   D DM M
( (O Ob be es se e   g gr ro ou up p   1 1) ) ( (O Ob be es se e   g gr ro ou up p   2 2) ) ( (O Ob be es se e   g gr ro ou up p   3 3) )
N 100 90 44 17
Age (yr) 12.4±2.5 12.0±2.5 12.5±2.1 13.2±2.7
BMI z-score 0.2±0.7 2.6±0.4a 2.8±0.4a 2.7±0.5a
Insulin (μU/ml) 10.3±4.5 13.3±4.1b,d 31.4±14.2a,b,c 20.7±8.0a,c,d
HOMA-IR 2.6±1.0 2.7±0.9b,d 6.7±2.8a,b,c 4.3±1.9a,c,d
Glucose 120 at OGTT  (mg/dl) - 108.1±15.0 112.2±15.9c 163.7±27.4c
Total cholesterol (mg/dl) 154.6±29.6 165.2±27.0a 169.7±34.3a 171.2±38.1a
HDL (mg/dl) 61.1±14.3 48.1±11.0 46.1±8.5 48.8±10.4
LDL (mg/dl) 77.5±22.4 93.3±26.4 98.3±31.8 87.6±33.2
Triglyceride (mg/dl) 69.1±25.0 120.4±58.1 131.4±46.4 141.1±83.9
A Ad di ip po oc cy yt to ok ki in ne es s n:29 - - -
Leptin (ng/ml) 7.2±4.9 50.7±19.5a 56.8±23.5a 50.7±12.4a
Adiponectin (μg/ml) 12.5±2.5 7.1±2.4a 6.2±2.5a 5.8±2.5a
TNF-α(pg/ml) 11±3.2 16.5±4.0a 17.1±4.0a 17.7±6.7a
a: Significantly diffent from control group (p<0,0001)
b: Significantly different between obese group 1 and 2, p<0.05
c: Significantly different between obese group 2 and 3, p< 0.05
d: Significantly different between obese group 1 and 3, p<0.05
Values are presented as the mean±SD
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Adiponectin is a Marker of Metabolic Syndromeal (8) showed that adiponectin levels in patients with T2DM
were lower than those of non-diabetic patients, and were 
particularly low in subjects with coronary artery disease. The
study by Weyer et al (24) demonstrated that hypoadiponecti-
nemia was more intensively related to the degree of insulin
resistance and hyperinsulinemia than to the degree of 
adiposity or glucose intolerance. Matsubara et al (33) have
shown that plasma adiponectin is negatively correlated with
serum triglyceride, atherogenic index, apo B, or apo E, and 
positively correlated with HDL-cholesterol or apo A-I levels.
These data suggest that low adiponectin concentrations are
associated with some of the well known risk factors for 
atherosclerosis such as low HDL-cholesterol levels or 
hypertriglyceridemia. It seems likely that a relationship exists
between hypoadiponectinemia and MS. 
An inverse correlation between serum adiponectin levels
and hyperinsulinemia, insulin resistance and dyslipidemia has
also been reported in the limited number of studies conducted
in children (3,10,28,29,31,34). Winer et al (35) performed a
standard OGTT and obtained baseline measurements for 
adiponectin, plasma lipid profile, CRP, IL-6 and leptin in a 
multiethnic cohort of 589 obese children and adolescents.
These authors found that the link between adiponectin levels
and a strong marker of inflammation, CRP, is independent of
insulin resistance and adiposity in obese children and 
adolescents. They suggested that adiponectin may have a
function as a biomarker of MS in childhood obesity. Ogawa
et al (36) have shown that hypoadiponectinemia was associated
with visceral fat accumulation and MS in obese boys. Our 
findings are consistent with previous reports suggesting that
serum adiponectin levels may serve as a marker for MS (36-40). 
In conclusion, among the adipocytokines evaluated in the
present study, adiponectin is the best indicator of MS and we
believe that the assessment of adiponectin levels might 
contribute to early intervention in obese children with MS. 
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